Phase II Study of Nitrosourea Fotemustine as Single-Drug Chemotherapy in Poor-Prognosis Non-Small-Cell Lung Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.1994.223
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

SCUBE3 Overexpression Predicts Poor Prognosis in Non-Small Cell Lung Cancer

BioScience Trends
BiochemistryHealthMedicineGeneticsMolecular Biology
2013English

Phase II Study of Gemcitabine Plus Oxaliplatin as First-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

Phase II Study of ACNU in Non-Small-Cell Lung Cancer: EORTC Study 08872

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
1991English

Low Level of 5-Hydroxymethylcytosine Predicts Poor Prognosis in Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2016English

Phase II Study of Docetaxel Alternating With Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2000English

Nociceptin Receptor Is Overexpressed in Non-Small Cell Lung Cancer and Predicts Poor Prognosis

Frontiers in Oncology
Cancer ResearchOncology
2019English

Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study

Research in Oncology
2007English

Overexpression of lncRNA EGFR‑AS1 Is Associated With a Poor Prognosis and Promotes Chemotherapy Resistance in Non‑small Cell Lung Cancer

International Journal of Oncology
Cancer ResearchOncology
2018English

A Phase II Study of High Dose Epirubicin in Unresectable Non Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
1992English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy